Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

STORY: Shares of Amgen on Tuesday were on track for their biggest percentage fall in more than two decades after the ...